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Enterotoxigenic Escherichia coli (ETEC) isolates are genetically diverse
pathological variants of E. coli deﬁned by the production of heat-labile (LT) and/or
heat-stable (ST) toxins. ETEC strains are estimated to cause hundreds of millions of
cases of diarrheal illness annually. However, it is not clear that all strains are equally
equipped to cause disease, and asymptomatic colonization with ETEC is common in
low- to middle-income regions lacking basic sanitation and clean water where ETEC
are ubiquitous. Recent molecular epidemiology studies have revealed a signiﬁcant
association between strains that produce EatA, a secreted autotransporter protein,
and the development of symptomatic infection. Here, we demonstrate that LT stimulates production of MUC2 mucin by goblet cells in human small intestine, enhancing
the protective barrier between pathogens and enterocytes. In contrast, using
explants of human small intestine as well as small intestinal enteroids, we show that
EatA counters this host defense by engaging and degrading the MUC2 mucin barrier
to promote bacterial access to target enterocytes and ultimately toxin delivery, suggesting that EatA plays a crucial role in the molecular pathogenesis of ETEC. These
ﬁndings may inform novel approaches to prevention of acute diarrheal illness as
well as the sequelae associated with ETEC and other pathogens that rely on EatA
and similar proteases for efﬁcient interaction with their human hosts.
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nterotoxigenic Escherichia coli (ETEC) strains are ubiquitous pathogens in low- to
middle-income regions, where they are a major cause of morbidity and mortality
due to diarrheal illness, particularly among young children (1). In the classical paradigm
of ETEC virulence, the organisms adhere to epithelial cells in the small intestine via
plasmid-encoded colonization factors, where they deliver heat-labile (LT) and/or heatstable (ST) enterotoxins that promote the net efﬂux of salt and water into the intestinal
lumen with ensuing watery diarrhea. Nevertheless, some features of ETEC illness suggest that this classical paradigm of molecular pathogenesis is far from complete (2).
Notably, ETEC strains cause illness that may range from mild disease to severe diarrhea
accompanied by rapid dehydration clinically indistinguishable from cholera (3–6). In
addition, ETEC and other bacterial enteric pathogens, including Shigella, have repeatedly been associated with poorly understood nondiarrheal sequelae (7), including environmental enteropathy (8), growth stunting (9–12), malnutrition (13), and cognitive
impairment (14, 15).
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RESULTS
ETEC heat-labile toxin stimulates production of a defensive mucin barrier.
Although the mucin layer in the small intestine is more penetrable than the colon (28),
it is possible that it is sufﬁcient to preclude the direct engagement of intestinal epithelial cells with ETEC required for effective toxin delivery (29). In addition, studies of rat
intestine (30, 31) and cell lines derived from a colonic cancer (32) suggested that cholera toxin, a homologue of LT, can stimulate goblet cell secretion of mucin. Accordingly,
LT treatment of enteroids derived from human small intestine resulted in signiﬁcantly
increased transcription of the MUC2 gene (Fig. 1a), while treatment of spheroids of
small intestinal cells, in which the apical surface of cells is oriented facing an internal
luminal cavity, resulted in the release of substantial amounts of MUC2 mucin into the
lumen compared to untreated controls (Fig. 1b). Similarly, treatment of polarized small
intestinal enteroid monolayers with LT and cholera toxin, but not a mutant E112K
enzymatically inactive version of LT (mLT), resulted in substantial increases in the secretion of MUC2 mucin (Fig. 1c) and a corresponding increase in integrity (Fig. 1d).
Enteroid monolayers treated with either forskolin or LT, but not untreated monolayers,
excluded the migration of ﬂuorescent beads to the epithelial surface, suggesting that
the induced mucin presents a signiﬁcant barrier (Fig. 1e and f). Altogether, these data
suggest that both LT and cholera toxin provoke intestinal epithelia to reinforce the
protective mucin barrier in the small intestine.
EatA promotes bacterial migration through the secreted mucin network. To
explore the hypothesis that the secreted EatA protease facilitates pathogen access to
host enterocytes by degrading the protective mucin barrier, we ﬁrst examined the
impact of EatA on the viscosity of the mucin matrix. Treatment of puriﬁed intestinal
mucin with wild-type (wt) recombinant passenger domain (rEatAp; Fig. 2a) resulted in
signiﬁcant reduction in viscosity (Fig. 2b) relative to either untreated mucin or mucin
treated with proteolytically inactive passenger domain (H134R). Likewise, polyclonal IgG
against EatAp prevented reductions in integrity (Fig. 2c). Next, we found that wild-type
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In addition to the canonical virulence factors, several more recently discovered plasmid-encoded proteins appear to be conserved within the ETEC pathovar (16, 17).
Among these is the EatA autotransporter protein (18), a member of the serine protease
autotransporters of the Enterobacteriaceae (SPATE) family (19). EatA, which shares
approximately 74% identity with the SepA autotransporter from Shigella ﬂexneri (20),
has recently been shown to degrade MUC2 (21), the major gel-forming mucin secreted
by goblet cells in both the small and large intestine (22). The 110-kDa secreted passenger domain of the EatA autotransporter contains the functional serine protease activity
centered on a catalytic triad formed by residues H134, D162, and S267 (18).
MUC2 is a large (;5,200 amino acids), heavily glycosylated protein with more than
80% of its mass comprised of glycans. The central portion of the protein is organized
into PTS domains that are comprised largely of repeated proline (P), threonine (T), and
serine (S) residues, where T and S hydroxyl groups serve as sites for O-glycosylation.
These densely glycan-rich PTS core regions of MUC2 are protected from proteolytic
degradation. The MUC2 apoprotein undergoes end-to-end dimerization at the C-terminal end of the molecule in the endoplasmic reticulum (23), followed by O-glycosylation
in the Golgi apparatus and further multimerization via von Willebrand D domains
(VWD) in the N-terminal region of the glycoprotein (24, 25). Ultimately, the MUC2
secreted by goblet cells expands to form large layered polymeric net-like structures
that serve as a primary mucosal defense against gastrointestinal pathogens and resident microbiota (26).
Interestingly, recent studies of ETEC isolated from a cohort of young Bangladeshi
children monitored from birth to 2 years of age (12) demonstrated that the presence
of the eatA locus was strongly associated with symptomatic diarrheal disease (27). The
studies reported here demonstrate that EatA degradation of mucin plays an essential
role in promoting effective pathogen-host interactions central to the molecular pathogenesis of ETEC.

Infection and Immunity

FIG 1 LT stimulates production and secretion of MUC2 mucin barrier by goblet cells in small intestinal epithelia. (a) Transcriptional
response (RT-PCR, MUC2) of small intestinal enteroids following treatment with heat-labile toxin (LT; 100 ng/ml overnight) compared
to untreated (ø) control cells. Shown are summaries of replicate experiments, each with 3 technical replicates (**, P = 0.02, MannWhitney, two-tailed, nonparametric analysis). (b) Small intestinal enteroids (spheroids) in which the apical surface of the enterocytes
is oriented to the inside of the sphere. Top panels represent untreated spheroids (ø) where MUC2 (green) is largely contained within
goblet cells. Nuclei are pseudocolored white (DAPI) and cell membranes are blue (CellMask). The hashed line depicts the region
enlarged below. Bottom, LT treatment of small intestinal spheroids results in MUC2 secretion into the lumen. (c) MUC2 mucin
production by polarized differentiated small intestinal enteroids. a-MUC2 immunoblot shows MUC2 present in apical supernatants of
(duplicate wells) untreated monolayers (ø) and following treatment with mutant LT (mLT), native LT, or cholera toxin (CT). (d) LT
treatment increases the integrity of the mucin barrier overlying enterocytes. Data represent time required for metal beads to traverse
mucin in supernatants obtained from LT-treated or control cells (ø). Shown are results of replicate experiments, each with 4 technical
replicates (***, P , 0.01 by Mann-Whitney, two-tailed nonparametric testing). (e) Graph depicts gap distances between 1-m m
ﬂuorescent beads and small intestinal enteroid monolayer surfaces comparing LT-treated cells to those treated with forskolin-treated
(FSK) or untreated (ø) monolayers. Data from duplicate experiments (n = 3 technical replicates) are differentially colored. Each symbol
represents the distance (z) between the bead front and the monolayer surface at selected points along the x-y axis. Dashed lines
represent median values. ****, P , 0.0001 by Kruskal-Wallis testing. (f) Volume projections of representative confocal z-stack images
of human small intestinal monolayers left untreated (ø) or treated with LT or forskolin (FSK). Cells were stained with CellMask (red)
and treated overnight, followed by addition of ﬂuorescent beads (1 m m). Confocal acquisition was ;45 min after addition of beads.

ETEC migrated signiﬁcantly faster through puriﬁed mucin than the eatA mutant (Fig. 2d),
suggesting that mucin serves as a substantial barrier to ETEC migration. Indeed, in ex
vivo explants of human small intestine (Fig. 2e; see also Movie S1 in the supplemental
material), we found that wild-type ETEC efﬁciently penetrated the mucin layer to engage
the epithelium, while the eatA mutant was excluded from contact with the epithelial surface. In addition, we used small intestinal enteroids in which the O-linked MUC2 sugars
were metabolically labeled with azide-modiﬁed galactosamine (GalNAz) followed by click
conjugation with the alkyne ﬂurophore (DBCO-Cy3) to highlight the secreted mucin
(red). Again, we found that the eatA mutant was trapped by small intestinal mucin
(Fig. 2f, Movie S2).
EatA is required for efﬁcient pathogen-host interaction and toxin delivery.
Efﬁcient delivery of ETEC enterotoxin requires intimate interaction of the bacteria with
the surface of target intestinal epithelial cells (IECs) (29). We found that in the absence
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FIG 2 EatA reduces mucin viscosity and promotes bacterial migration through intestinal mucin. (a) Putative EatA passenger domain
structure, protease subdomain (blue), showing active site with the H134, D162, S267 catalytic triad highlighted in yellow (inset) and
the domain of unknown function (DUF) in green. (b) Wild-type recombinant EatA passenger domain (rEatAp), but not the passenger
bearing a mutation in the serine protease catalytic triad (H134R), reduces the integrity of puriﬁed MUC2 mucin. Symbols represent
technical replicates combined from a total of n = 5 experimental replicates. (c) Antibodies against rEatAp inhibit EatA effects on
mucin integrity. (Symbols indicate technical replicates from n = 2 experiments.) (d) EatA is required for efﬁcient ETEC migration
through puriﬁed MUC2 mucin. Each symbol represents average accumulated ﬂuorescence intensity of gfpmut3.1-expressing wild-type
and eatA mutant bacteria over time following introduction into m -channel slides (ibidi m -slide vi 0.4). Data represent progression of
ﬂuorescently labeled bacteria along their respective channels in images acquired ;14 mm from the point of entry. (e) EatA is
required for penetration of the mucin layer in human intestinal explants in vitro. The graph at the left depicts the percentage of wt
and eatA mutant (D) bacteria expressing pGFPmut3.1 that have penetrated the mucin layer at 15 min after infection (3 technical
replicates in each of two independent experiments from separate tissue donors are shown by color). P = 0.0006 by analysis of
variance (ANOVA). Shown on the right are representative images acquired by two-photon microscopy of bacteria (green) and
penetration into the mucin layer over time. The edge of the intestinal mucin is depicted by the blue line and the surface of the
intestine by the white line. Intestinal cells autoﬂuoresce purple. (f) Two-photon microscopy images of small intestinal enteroids
metabolically labeled with GalNAz to highlight secreted mucin (red).

of eatA, ETEC bacteria were incapable of effectively migrating through MUC2 puriﬁed
from small intestinal enteroids and were as impaired as an immotile (ﬂiC) mutant, while
pretreatment of MUC2 with rEatAp restored migration (Fig. 3a). Similarly, adherence of
the eatA mutant ETEC to target small intestinal enteroid epithelial cells (Fig. 3b, Fig. S1)
was signiﬁcantly impaired relative to wild-type ETEC, as was delivery of heat-labile
toxin (Fig. 3c). Collectively, these data suggest that eatA plays an essential role in promoting effective ETEC pathogen-host interactions.
Identiﬁcation of a subdomain required for binding and degradation of MUC2
mucin. MUC2 mucin produced by goblet cells in the small intestine is heavily glycosylated.
Interestingly, recent structural analysis of SepA suggested that an 80-amino-acid subdomain
within the passenger domain could represent a carbohydrate binding module (CBM) (33).
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To investigate the importance of the corresponding region in EatA (Fig. 4a) to virulence, we
ﬁrst replaced the passenger subdomain of unknown function encompassed by amino acids
E541 to S616 with a stretch of 8 histidines (DUF::H8). The resulting protein was secreted as
efﬁciently as the parent molecule (Fig. 4b) and retained the ability to degrade the AAPL synthetic peptide (Fig. 4c). While the passenger domain containing a single point mutation in
the catalytic triad (H134R) colocalized with MUC2 in sections of human intestine (Fig. 4d),
we observed appreciably less interaction between MUC2 and the DUF::H8 mutant in
sections of human ileum (Fig. 4e, Fig. S2) and in the lumen of small intestinal spheroids
(Fig. 4f). Similarly, the DUF::H8 passenger protein exhibited only weak interaction with puriﬁed MUC2 (Fig. 4g), and the mutant protein was incapable of efﬁciently degrading MUC2
(Fig. 4h, Fig. S3A). Importantly, antibodies speciﬁc to the E541-S616 peptide inhibited the
activity of the parent molecule (Fig. S3B to D). Complementation of the eatA mutant in trans
with a plasmid expressing the DUF::H8 protein also failed to restore ETEC interaction with
target epithelial cells (Fig. 4i), further suggesting that this region is essential to EatA function. Although interactions of EatA with heavily glycosylated MUC2 molecules may involve
carbohydrate moieties, we did not observe signiﬁcant binding to glycan microarrays (Data
Set S2) with either the full-length recombinant EatA passenger domain or the mutant lacking the putative carbohydrate binding module encompassed by the E541-S616 subdomain.
Likewise, nanoparticles in which Spy-tagged EatA (K535-S616) was conjugated to the surface of SpyCatcher-mi3 (34, 35) were not sufﬁcient to direct MUC2 binding (Fig. S4).
Collectively, these studies suggest that while this region of the passenger domain is critical
for mucin interactions, it likely acts in concert with the proteolytic subdomain to engage
and degrade MUC2.
DISCUSSION
The studies presented here potentially provide a biological basis for the recent ﬁnding that the presence of eatA is strongly associated with development of symptomatic
February 2022 Volume 90 Issue 2 e00572-21
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FIG 3 Both EatA and motility are required to penetrate MUC2 and engage small intestinal epithelia.
(a) Shown are data from Transwell mucin migration assays in which wild-type H10407 (wt) or the
eatA or ﬂagellin (ﬂiC) mutants (;105 CFU) were added to the upper chamber containing MUC2 mucin
harvested from small intestinal enteroids. Data are expressed as the percentage of inoculum
recovered from the lower chamber after 2 h. rEatAp represents complementation with exogenous
EatA passenger domain (50 m g/ml) added at the time of infection. Bar graphs at the right
demonstrate mean recovery 6 standard errors of the means in the absence of MUC2. (b) EatA
facilitates bacterial access to epithelial cells. Shown are wt or mutant bacteria adherent to small
intestinal enteroid monolayer epithelial cells. The eatA mutant was complemented with either a
recombinant eatA expression plasmid (pTW5016) or the vector control (pWSK29). Shown are the
results of three replicate experiments (separated by color) with each symbol (n = 40) representing a
technical replicate. (c) EatA is required for efﬁcient ETEC delivery of heat-labile toxin to enteroid
monolayers. (Shown are cAMP levels in target epithelial cells infected with wild-type or mutant
bacteria 2 h after infection.) P values in each panel reﬂect comparisons by ANOVA with
nonparametric Kruskal-Wallis testing (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P , 0.0001).
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FIG 4 (a) Model of the EatA passenger domain showing the relative location of the protease (blue) and putative CBM (green). (b)
Coomassie-stained SDS-PAGE of TCA-precipitated culture supernatants showing migration of the recombinant passenger domain
(arrows) from E. coli Ig10B expressing EatA, EatA bearing a polyhistidine replacement of the domain of unknown function (DUF::H8),
and the H134R/DUF::H8 double mutant passenger protein. (c) The domain of unknown function is not required for proteolytic
activity. Shown are the results of AAPL oligopeptide cleavage experiments for using the wild-type EatA passenger protein (EatAp)
and mutant passenger proteins. Results represent means and standard deviations from 3 separate experiments. (d) EatA passenger
domain colocalizes with MUC2 mucin. Panels show representative confocal images of proteolytically inactive EatA (H134R) passenger
domain interacting with MUC2 secreted into the lumen of human intestinal explants and retained in goblet cells. (e) Optimal binding
to small intestinal MUC2 requires the subdomain from E541-S616. The graph depicts colocalized binding of H134R or H134R/DUF::H8
protein to MUC2 in sections of small intestine shown in Fig. S2. (f) Binding to secreted MUC2 requires the E541-S616 region. Shown
are maximal intensity projections of confocal microscopy z-stack images of sections of small intestinal spheroids stimulated with
heat-labile toxin to stimulate release of MUC2 into the lumen. Replicate daughter sections were incubated with the H134R passenger
protein (left) or the DUF::H8 mutant protein (right). The graph depicts binding of EatA H134R and DUF::H8 passenger domains relative
to target MUC2 (n = 33 regions from 30 spheroids; ****, P , 0.0001, two-tailed Mann-Whitney). (g) MUC2 pulldown using EatA
(H134R) passenger domain or the H134R/DUF::H8 passenger domain as bait. The graph represents a summary of three replicate
experiments (**, P = 0.008) in two-tailed Mann-Whitney nonparametric testing. (h) MUC2 degradation requires the domain of
unknown function. (i) Optimal ETEC engagement of small intestinal enteroids requires the E541-Q617 region of the passenger
domain. Shown are the combined results of three experimental replicates, each with 10 technical replicates/experiment (n = 30/
group). ****, P , 0.0001 by ANOVA (Kruskal-Wallis).

disease in young children infected with ETEC (27) and suggest that mucin degradation
plays a critical role for these pathogens. It is clear from earlier studies that enterotoxin
delivery by these bacteria requires direct enterocyte engagement (29), and the data
presented here indicate that in the absence of an effective mucin-degrading enzyme,
February 2022 Volume 90 Issue 2 e00572-21
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even the relatively loose layer of mucin overlying the small intestinal epithelia appears
to be sufﬁcient to mitigate interaction of ETEC with the host.
This barrier is further reinforced by the host response to LT. Using enteroids propagated from human small intestine, we show that LT and the closely related cholera
toxin are potent secretagogues for MUC2 mucin. Therefore, while the layer of mucin
overlying small intestinal epithelia is thought to be more penetrable relative to that in
the colon, it does not appear to be static, and EatA may have evolved to counter what
would otherwise be an effective host defense strategy.
These data may also add another layer of complexity to the interpretation of epidemiologic studies that to date have deﬁned the ETEC pathovar simply by the presence
of heat-labile and heat-stable toxins. The large proportion of asymptomatic ETEC colonization in these studies potentially confounds attempts to accurately assess the burden of diarrheal illness attributable to ETEC (36). The present studies provide further
data in support of the concept that ETEC are not equally equipped to cause disease.
Notably, eatA originally discovered on a virulence plasmid of H10407 (18), a strain isolated from a patient with cholera-like illness in Bangladesh, has been identiﬁed subsequently in other strains with clear metadata linking them to severe cholera-like illness
(5, 6). H10407 has been the subject of multiple controlled human infection studies,
largely because relative to other strains it reliably causes signiﬁcant diarrheal illness
(37–39).
The presence of SepA, a homologue that shares more than 70% identity with EatA,
has been strongly linked to virulence of other pathogens, including enteroaggregative
E. coli (EAEC) (40, 41). Indeed, in the interrogation of more than 90 genomes from EAEC
strains collected in the Global Enteric Multicenter Study (GEMS) (1) for potential virulence genes, sepA was recently shown to have the strongest association with the development of moderate-to-severe diarrheal illness (41). The role of SepA in the virulence
of Shigella species, including Shigella ﬂexneri 5a, where SepA was originally discovered
(20) on the large virulence plasmid, is currently unknown. However, given that some
Shigella ﬂexneri 2a as well as other Shigella species, including Sonnei species, make
EatA (42), these pathogens might also utilize these proteases to degrade the thicker
layer of mucin in the colon.
Collectively, the information emerging from molecular epidemiology studies (27),
as well as the data presented here, suggest that EatA plays a crucial role in the molecular pathogenesis of ETEC. These ﬁndings may inform novel approaches to prevention
of acute diarrheal illness as well as the sequelae associated with ETEC and other pathogens that rely on EatA and similar proteases for efﬁcient interaction with human hosts.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. Bacterial strains used in this study are presented in Table S1. Bacterial cultures were routinely incubated with aeration at 37°C in Luria-Bertani (LB)
broth (10 g tryptone, 5 g yeast extract, and 10 g NaCl per liter) or on LB agar plates unless indicated otherwise. Antibiotics were added as appropriate. For infection assays, overnight-grown liquid cultures
diluted to 1:100 in LB broth were incubated for ;2 h to mid-log phase.
Propagation of enteroids and epithelial monolayer culture. Detailed procedures for growth and
maintenance of these cells have been described previously (43, 44). Brieﬂy, cryopreserved cells were
resuspended in Matrigel (BD Biosciences), and 15 m l of the suspension was seeded into each well of a
48-well tissue culture plate. Cells were maintained in 50% conditioned medium (CM) consisting of a 1:1
mixture of L-WRN conditioned medium and primary tissue culture medium, advanced Dulbecco’s modiﬁed Eagle’s medium (DMEM)-F12 containing 20% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml
penicillin, and 0.1 mg/ml streptomycin, supplemented with 10 m M of Y-27632 (ROCK inhibitor; Tocris
Bioscience) and 10 m M SB431542 (TGFBR1 inhibitor; Tocris Bioscience). To obtain a polarized epithelial
monolayer, cells were pooled from 10 wells, washed in phosphate-buffered saline (PBS), and trypsinized
before seeding onto a 75-mm, 0.4-m m-pore polycarbonate membrane (Transwell, Corning) coated with
type IV collagen (34 m g/ml) in sterile cell culture water. CM was added to upper and lower wells and
maintained at 37°C, 5% CO2 for 5 days. Fresh CM was added every 2 days. Following conﬂuence, medium
was replaced with cell differentiation medium (DM) containing 5% CM in DMEM-F12 medium supplemented with 20% FBS, 2 mM L-glutamine, and 10 m M Y-27632. Fresh DM was added daily for 2 days for
monolayer differentiation prior to treatment with toxin.
Spheroid propagation and processing. For spheroid cultures, cells suspended in Matrigel were
seeded as 15-m l droplets into individual wells of a 48-well tissue culture plate and grown for 3 days in
February 2022 Volume 90 Issue 2 e00572-21
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50% CM. Spheroids were then diluted in 150 m l Matrigel (1:10 dilution from initial volume), reseeded as
50-m l droplets in a 24-well tissue culture plate, and grown for 5 days in 50% CM. Finally, CM was
replaced with cell differentiation medium containing 5% CM and grown for 3 days. Mucin production
was stimulated by the addition of E. coli LT (100 ng/ml). Resulting spheroids were ﬁxed with 4% paraformaldehyde (PFA) for 30 min at 37°C and 30 min at room temperature, washed 3 with PBS, and embedded in 5% Luria agar prior to being processed as parafﬁn blocks for sectioning.
Confocal microscopy. For EatA binding, spheroid sections were deparafﬁnized, hydrated, unmasked,
and incubated with 10 m g/ml of EatAH134R or EatAH134R-DUF-his at 4°C overnight. Following incubation,
unbound EatA was washed off by rinsing the slides 3 with PBS. Muc2 mucin and EatA signals were
detected with anti-Muc2 rabbit polyclonal (1:200; sc-15334; Santa Cruz) and anti-EatA mouse polyclonal
(1:100; in-house) primary antibodies, followed by ﬂuorescence-tagged goat anti-rabbit IgG Alexa Fluor 488
(1:200; Invitrogen) and ﬂuorescence tagged goat anti-mouse IgG Alexa Fluor 594 (1:200; Invitrogen) secondary antibodies. Cell nuclei were counterstained with 49,6-diamidino-2-phenylindole (DAPI) (1:1,000)
and mounted using prolong gold antifade reagent (Invitrogen). Images were captured and analyzed on a
Nikon C2 confocal microscope equipped with NIS-Elements AR 5.11.01 software (Nikon).
Human intestinal explants and two-photon imaging. Freshly isolated sections of human small
and large intestine were obtained at ileocolonic resection surgery from the Digestive Diseases Research
Core Center at Washington University (DDRCC). The muscle layer was carefully removed, and the tissues
were supported on a 70-m m cell strainer mesh placed in a custom imaging chamber. The tissue was perfused from the serosal side with oxygenated DMEM throughout imaging. Wild-type (jf2450) and eatA
mutant (jf4738) green ﬂuorescent protein (GFP)-expressing bacteria were grown in Luria broth containing ampicillin (100 m g/ml) overnight at 37°C, 200 rpm, and then diluted 1:100 and grown to an optical
density at 600 nm (OD600) of ;0.125 immediately prior to the experiment. Four hundred microliters of
undiluted culture was then mixed with 50 m l of a 1:100 dilution of 1.75-m m ﬂuorescent microspheres
(19392; Polysciences); 450 m l of the bead/culture suspension was added to the epithelial surface of
individual tissue sections. Images were acquired using a custom-built two-photon microscope in the
Washington University In Vivo Imaging Core (IVIC) equipped with an Olympus XLUMPLFLN 20,
1.0-numeric-aperture water-immersion objective. Fluorescence was excited using a Ti-Sapp laser
(Chameleon Vision II; Choherent) tuned to 890 nm and emission collected using 495/540/570-nm
dichroic ﬁlters (Semrock) and 3 head-on bi- and multialkali PMTs (Hamamatsu). Slidebook digital microscopy software (Intelligent Imaging Innovations) was used for hardware control and acquisition of twodimensional time-lapse recordings and z-stack images. Imaris 9.5 (Oxford Instruments) was used for data
rendering and analysis.
Metabolic labeling of enteroids. Enteroid monolayers were metabolically labeled overnight with medium containing 50 m M GalNaz (N-azidoacetylgalactosamine, tetra-acylated; CLK-1086; Jena Biosciences).
After washing with fresh media, resulting azide-functionalized glycoconjugates were reacted with DBCO-Cy3
(Kerafast), and nuclei were stained with Hoechst 3342 (B2261; Sigma).
Mucin puriﬁcation. Human MUC2 mucin was recovered from culture supernatants of LS174T cells
(ATCC CL-188) by ultraﬁltration as previously described (21).
Mucin migration assays. To evaluate bacterial migration through a mucin network, mucin was ﬁrst
harvested from human small intestinal enteroid monolayers. Approximately 48 h after differentiation,
medium was aspirated and mucin was carefully retrieved using a 1.8-cm-wide cell scraper (Corning),
leaving the cell monolayer undisturbed; 200 m l of the harvested mucin was dispensed onto 3-m m polycarbonate Transwell membranes in a 24-well plate. Five hundred microliters of base medium (Advanced
DMEM-F12 containing 20% FBS and 2 mM L-glutamine) was added to the bottom wells. Fifty microliters
of bacterial suspension containing 105 CFU was dispensed into the wells containing mucin, and plates
were incubated at 37°C, 5% CO2, for 2 h. Medium was then collected from the bottom well, and serial
dilutions were plated on Luria agar with appropriate antibiotics. Puriﬁed EatA protein was added, where
indicated, at a ﬁnal concentration of 50 m g/ml.
To evaluate the impact of EatA on migration through mucin to the epithelial surface, the upper
chamber of monolayer cultures of small intestinal enteroids was inoculated by with ;105 CFU of wildtype or mutant bacteria. Plates were then incubated at 37°C in 5% CO2. After 2 h, medium was gently
aspirated and washed 3 times with prewarmed medium to remove unbound bacteria, and cells were
then ﬁxed with 4% paraformaldehyde for 30 min at room temperature. The ﬁxed samples were then
blocked with PBS containing 1% bovine serum albumin (BSA) for 30 min and immunostained with rabbit
anti-O78 antibody followed by cross-absorbed goat anti-rabbit Alexa Fluor 594-conjugated IgG (H1L)
(A-11072; ThermoFisher). Membranes with ﬂuorescently labeled samples were excised and mounted
onto glass slides with ProLong Gold (P36930; ThermoFisher Scientiﬁc) and imaged with a Zeiss Axio
Imager M2 plus wide-ﬁeld ﬂuorescence microscope, capturing 10 random ﬁelds per membrane to enumerate bacteria/ﬁeld.
To evaluate the impact of EatA on kinetics of ETEC migration through mucin, equal numbers of GFPexpressing eatA mutant (jf4737) or wild-type H10407 (jf2451) were loaded into adjacent wells of m -channel slides (ibidi, v. 0.4) containing MUC21 concentrated supernatants from LS174T cells. Slides were
maintained at 37°C, 5% CO2, and 80% humidity in a stage-top environmental chamber (ibidi). Confocal
images were collected at 3-min intervals at distances of 1.8, 4.5, 8.8, and 13.7 mm from the inoculation
well, and mean ﬂuorescence intensity was recorded over time to assess migration of GFP-expressing
bacteria.
Mucin integrity assays. To examine the impact of EatA and EatA mutants on mucin integrity, we
used a microscale rolling-ball viscometer apparatus as described by Tang (45). Brieﬂy, puriﬁed mucin
treated with protease or controls was loaded into a 100-mm glass capillary tube (Smurray G119/02)
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sealed at one end with modeling clay (Plastalina; Van Aken); 0.5-mm steel balls were introduced into the
open end of the tube and maintained in place with a magnet. Tubes were maintained on a 20° incline,
and the time required for the ball to traverse a distance of 80 mm following release of the magnet was
recorded, averaging a minimum of 4 technical replicates/experiment.
Immunoblotting. MUC2 immunoblotting was performed as described previously (21). Brieﬂy, after
EatA treatment, samples were separated by discontinuous 4% Tris-glycine SDS-PAGE, the gel was
reduced by agitation for 10 min in a 10 mM DTT solution in Tris-glycine-isopropanol blotting buffer to
improve transfer of the high-molecular-mass MUC2, and then samples were blotted onto nitrocellulose,
blocked with 5% (wt/vol) milk in PBST, and probed with anti-MUC2 rabbit polyclonal (H-300; sc-15334;
Santa Cruz) (1:2,000), followed by goat anti-rabbit horseradish peroxidase (HRP)-conjugated sc-2030
(Santa Cruz) (1:5,000). Bound antibody was visualized by chemiluminescence using Clarity ECL Western
blot substrate (Bio-Rad).
MUC2 dot blotting. MUC2 dot blots were performed with supernatants from the apical compartment of small intestine enteroid monolayers grown as described above. Brieﬂy, cells were grown in
Transwells to conﬂuence and differentiated for 2 days, and then duplicate wells were treated overnight
with 100 ng/ml of native LT, mutant LT (mLT; E112K), or cholera toxin (CT). Supernatants were collected
and spun down at 10,000  g for 1 min to remove cellular debris. Serial dilutions (1:2 to 1:64) of the corresponding supernatants were performed in PBS. Serial dilutions (1:2 to 1:128) of concentrated LS174T
supernatant containing MUC2 (described above) were used as positive controls. Two microliters of each
dilution was spotted onto a nitrocellulose membrane, allowed to dry, blocked with 5% (wt/vol) milk in
PBST, and probed with anti-MUC2 (clone F2; sc-515032; Santa Cruz) (1:500) followed by horse antimouse HRP conjugate (7076; Cell Signaling) (1:1,000). Bound antibody was visualized by chemiluminescence using Clarity ECL Western blot substrate (Bio-Rad).
Glycan array screening. Glycan arrays were used as previously described (44) to examine the potential interaction of the EatA passenger domain with carbohydrates. Brieﬂy, these glycan arrays that contained 737 separate features (including control spots) were fabricated, validated, and analyzed as
reported earlier (46–49). After blocking overnight at 4°C, using 3% (wt/vol) BSA in PBS (200 m l/well),
slides were washed 6 times with PBST (PBS with 0.05% Tween 20, 200 m l/well). Biotinylated rEatA-6His,
or biotinylated rEatAp-DUF::His8, was diluted to ﬁnal concentrations of 5 and 50 m g/ml in lectin buffer
containing 20 mM Tris, 150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, pH 7.4, with 3% BSA and 1% human
serum albumin (Millipore Sigma). In one pair of assays, 100 m l of each sample was incubated on the array
for 2 h (37°C, 100 rpm). The arrays were washed and incubated (1 h at 37°C; 100 rpm) with Cy3-labeled
streptavidin (S6402; Millipore Sigma) at a ﬁnal concentration of 2 m g/ml in lectin buffer (1 h at 37°C;
100 rpm). In a second pair of experiments, each sample was precomplexed with streptavidin (10:1 protein-streptavidin), followed by incubation on the array for 2 h (37°C, 100 rpm). Slides were then washed
7 times in PBST (200 m l/well), immersed in wash buffer (5 min at room temperature), and centrifuged
(5 min at 200  g). Slide scanning was performed on an InnoScan 1100AL ﬂuorescence scanner
(Innopsys; Chicago, IL) at 5-m m resolution (excitation at 532 nm and emission at 575 nm) and data analyzed using GenePix Pro 7.0 (46). A complete list of array components is available in Data Set S1 in the
supplemental material.
Molecular cloning. To produced properly folded polyhistidine-tagged EatA passenger domains, the
eatA gene was ﬁrst ampliﬁed in two fragments using primer pairs jf110414.1/jf02215.5 and jf022515.6/
jf022515.7 (Table S3), yielding amplicons NcoI-eatA5-2588His-XhoI and XhoI-eatA259-4095-HindIII, respectively. These fragments were sequentially introduced into the corresponding restriction sites on pBAD/
myc-HisB (Table S2) to produce pTV001, which encodes EatA bearing a polyhistidine tag at a permissive
site between amino acids 86 and 87. Similarly, a plasmid was constructed to replace the region encoding
the domain of unknown function corresponding to E541-S616 of EatA with an 8 polyhistidine tag.
Brieﬂy, primer sets jf110414.1/jf061615.3 and jf061615.2/jf022515.7 were used to generate amplicons
NcoI-eatA5-16209His-XhoI and XhoI-eatA1849-4095-HindIII, respectively. These fragments were then sequentially cloned into the corresponding sites on pBAD/myc-HisB, yielding pTW5126.
To generate the eatA complementation plasmid, pTW5016, full-length eatA DNA sequence was ampliﬁed
from H10407 with primer set jf081718.1 and jf081718.2. The PCR product was ligated to a low-copy-number
plasmid vector pWSK29 (BamHI/SalI) by Gibson assembly (New England Biolabs). Similarly, pTW5128 was
constructed by amplifying the mutated eatA sequence from pTW5126 with primers jf071519.1 and
jf071519.2. The amplicon was then ligated into PstI-digested pTW5016 by Gibson assembly.
The region corresponding to K535-P618 of EatA was ampliﬁed using primers jf070220.1/0.2 and
cloned by Gibson assembly to replace the mClover3 sequence of pSpyTag003-mClover3, which was
ampliﬁed using primers jf070220.3/0.4. The DNA sequence of the resulting plasmid pJMF0820 conﬁrmed
placement of the region encoding the EatA subdomain in-frame with 59 SpyTag and 39 6His tags.
Plasmids pTV001 and pTW5126 are deposited with Addgene with accession numbers 130265 and
129732, respectively.
Recombinant protein expression and antibody puriﬁcation. To prepare untagged recombinant
native (rEatAp) and inactivated (rEatAp-H134R) proteins, passenger domains proteins were expressed from
strains jf1960 and jf1975 (Table S1), and concentrated culture supernatants were then puriﬁed by anion
exchange followed by size exclusion chromatography, as previously described (21). The mutant passenger
domain in which the domain of unknown function was replaced by a polyhistidine tag (rEatAp-DUF::His8)
was expressed from jf5132. Concentrated culture supernatant was then exchanged into PBS and the
secreted recombinant protein puriﬁed using immobilized metal afﬁnity chromatography, as described previously (50).
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Production of SpyCatcher-EatAK535-P618 nanoparticles. BL21-CodonPlus (DE3)-RIPL transformed
with pJMF0820 was grown overnight in Luria-Bertani (LB) medium containing 50 m g/ml kanamycin at
37°C. The following morning, saturated cultures were diluted 1:100 in 1 liter of fresh LB medium supplemented with kanamycin and 0.8% glucose (wt/vol) and grown at 37°C, 200 rpm, to an A600 of ;0.5.
Cultures were then induced with isopropyl b -D-1-thiogalactopyranoside (IPTG; 0.5 mM) and incubated at
30°C for an additional 4.5 h. Following centrifugation, bacterial pellets were frozen at 280°C. Each of 4 pellets from 250 ml of culture was resuspended in 30 ml of immobilized metal afﬁnity chromatography
(IMAC) lysis buffer containing 75 mM sodium phosphate, pH 7.5, 500 mM NaCl, 1 mM imidazole, cOmplete
mini EDTA-free protease cocktail (Roche), 1 mg lysozyme, 1 mg DNase, and 0.5% Triton X-100. Following
sonication and centrifugation at 20,000  g for 20 min, polyhistidine-tagged recombinant proteins were
puriﬁed from the clariﬁed lysates by IMAC as previously described (35), yielding SpyTagged-EatAK535-P618.
His6-SpyCatcher-mi3 was produced as previously described (34). Brieﬂy, after transformation of
BL21-CodonPlus (DE30)-RIPL cells to kanamycin resistance, transformants were grown overnight in
Luria-Bertani broth containing kanamycin (50 m g/ml), chloramphenicol (15 m g/ml), and streptomycin
(10 m g/ml), diluted 1:100 into 4 500-ml ﬂasks with fresh medium, allowed to grow at 37°C to an OD600
of ;0.7, and then induced with 0.5 mM IPTG overnight at room temperature at 250 rpm. Bacteria were
harvested by centrifugation and lysed in 30 ml of IMAC lysis buffer. HisSpyCatcher-mi3 was then puriﬁed
using afﬁnity precipitation by the addition of nickel chloride to clariﬁed lysates at a ﬁnal concentration
of 200 m M and incubation at room temperature for 10 min. Precipitated protein was collected by centrifugation at 11,000  g for 10 min and the resulting pure protein pellet redissolved in 10 ml of 50 mM
Tris, pH 9, 10 mM EDTA. Polyclonal IgG from the sera of mice previously immunized with rEatAp (21), or
normal mouse controls, was puriﬁed by protein G afﬁnity chromatography.
Antibody preparation. Antibodies were puriﬁed from the sera of 20 mice that were vaccinated
intranasally three times 2 weeks apart with 20 m g of recombinant EatA passenger domain (rEatAp)
mixed with 1 m g of heat-labile toxin, as described previously (21). Two weeks after the ﬁnal dose, mice
were sacriﬁced and serum collected. The sera were screened for aEatAp IgG antibodies by enzymelinked immunosorbent assay (ELISA), and 10 sera with the highest aEatAp titers were pooled. To isolate
antibodies speciﬁc to the EatA domain of unknown function from K535-P618, an afﬁnity column was
prepared by coupling 3.6 mg of the SpyTag-EatAK535-P618-His protein to AminoLink plus resin (Thermo) in
100 mM sodium citrate, 50 mM sodium carbonate, pH 10, at room temperature in a 10-ml glass column
for 4 h. The resin was then washed with 5 ml of PBS, and 5 ml 50 mM sodium cyanoborohydride in PBS
was added and allowed to react overnight at 4°C. The resin was then washed with 4 ml of quenching
buffer (1 M Tris, pH 7.4); 2 ml of quenching buffer containing 50 mM sodium cyanoborohydride was
added and the suspension mixed at room temperature for 30 min. The resin was then washed with
10 ml PBS prior to antibody capture. Pooled aEatAp sera were diluted 1:1 with PBS and mixed with the
resin for 1 h at room temperature. The resin was washed three times with 5 ml of PBS, and bound antibodies were then eluted in 10 ml 100 mM glycine, pH 2.7; 1-ml fractions of eluate were collected in
tubes containing 50 m l of neutralization buffer (1 M Tris, pH 9). Fractions containing aDUF antibodies
and examined by ELISA were then pooled and dialyzed against PBS.
Toxin delivery assays. Enteroid-derived monolayer of polarized cells was obtained in a 24-well cell
culture plate using the method described above. Cells cultures were treated with phosphodiesterase
(PDE) inhibitors vardenaﬁl (Y0001647; Millipore Sigma), cilostazol (PHR1503; Millipore Sigma), and rolipram (R6520; Millipore Sigma) 1 h prior to infections at a ﬁnal concentration of 25 m M. The cells were
then inoculated by dispensing 100 m l containing ;105 CFU to individual wells. The samples were incubated at 37°C in a 5% CO2 incubator for 2 h, after which the medium was replaced with fresh, prewarmed medium containing PDE inhibitors and incubated for 1 h. Cellular cyclic AMP (cAMP; Arbor
Assays) levels were used as a readout for the efﬁciency of LT delivery as previously described (51).
Oligopeptide cleavage. p-Nitroanilide substrate cleavage was carried out as previously described
(18). Brieﬂy, 1 mM N-succinyl-Ala-Ala-Pro-Leu-p-nitroanilide (S8511; Sigma) dissolved in 100 mM morpholinepropanesulfonic acid, pH 7.3, 200 mM NaCl was digested at 37°C with 15 m g of enzyme in a ﬁnal
volume of 300 m l. The reaction was monitored at 405 nm and initial rates expressed as measured optical
density (mOD)/min.
Molecular modeling. The structure of the EatA passenger domain (GenBank accession no. AAO17297.1,
amino acids 57 to 1062) was aligned with the corresponding region of SepA (33) using the Multialign Viewer
extension (52) within UCSF Chimera (53) v1.13.1, developed by the Resource for Biocomputing, Visualization,
and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311.
Theoretical homology models of the EatA passenger were generated against the SepA template Protein Data
Bank entry 5J44 using the Chimera interface to Modeller (54).
Ethics statement. Studies included here involving human tissues were approved by the Institutional
Review Board at Washington University in Saint Louis School of Medicine. Deidentiﬁed human small intestinal enteroids and fresh explants of human intestine were obtained from the DDRCC under approved
protocols 201406083 and 201804112, respectively. Mouse studies were conducted under protocol 200438, approved by the Institutional Animal Care and Use Committee at Washington University in Saint
Louis School of Medicine.
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